(Q37650211)

21 August 2017

1 reference

title

Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now? (English)

1 reference

positron emission tomography

21 August 2017

main subject

1 reference

N George Mikhaeel

1

1 reference

21 August 2017

publication date

1 December 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

50

1 reference

21 August 2017

issue

12

1 reference

21 August 2017

page(s)

1931-1936

1 reference

The role of FDG PET in the management of lymphoma: what is the evidence base?

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275610

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275610

Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275610

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275610

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275610

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275610

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275610

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275610

Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275610

Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275610

Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275610

[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275610

FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275610

High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275610

18F-FDG PET in non-Hodgkin's lymphoma: qualitative or quantitative?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275610

Overview of early response assessment in lymphoma with FDG-PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275610

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275610

Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275610

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275610

Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275610

Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275610

10.3109/10428190903275610

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference